1. J&J’s merger with Pfizer will allow it to squeeze $500 million per year out of its cost structure and enable it to break even on the transaction in 2009--a year earlier than expected.
2. It is increasing its quarterly dividend, this time by 10.7%.
Cost savings are jewels under the feet of mergers and acquisitions
[Click here for full story at: BUSINESSWEEK.COM]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment